Brendan Murphy, world history and Holocaust studies teacher at Marist School in Atlanta, Georgia, gave a presentation on the ...

Miles Lewis had his first seizure at 4 years old. He was diagnosed with epilepsy after those seizures kept happening He was put on medication, but eventually a team of doctors at Johns Hopkins All ...

Between March 7 and March 18, the complainant was manipulated and also coerced into making eight large transfers totalling Rs ...

Audience members hold bottles of food dye as part of an interactive activity during a Ram Talks lecture that explained the dangers of bioaccumulation in chocolate March 25. The go ...

Executive dysfunction in drug-resistant epilepsy is common and linked to greater ASM load/number of ASMs and increased likelihood of unemployment, a new study shows.

The paper brings together insights from both laboratory discoveries and real-world patient outcomes, showing that ketogenic diets do far more than reduce seizures. The review outlines how these strict ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more than 50% for some patients as it looks to position itself to become the ...

Epileptic seizures alter sleep by prolonging the stage that's central to memory formation, potentially predisposing the brain to "remember" how to trigger subsequent seizures more easily, a small ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are ...

A drug that has long been used to treat seizures has shown promise as a potential means of Alzheimer’s prevention, a new study suggests. The anti-seizure medication, levetiracetam, was first approved ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...